Media stories about SteadyMed (NASDAQ:STDY) have been trending somewhat positive on Tuesday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. SteadyMed earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.2583569577488 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of SteadyMed (NASDAQ STDY) remained flat at $3.10 during midday trading on Tuesday. The company had a trading volume of 2,576 shares. SteadyMed has a 12-month low of $2.25 and a 12-month high of $9.70. The firm’s market capitalization is $82.32 million. The firm’s 50-day moving average price is $3.25 and its 200 day moving average price is $3.26.
SteadyMed (NASDAQ:STDY) last released its earnings results on Friday, August 11th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.01). The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.26 million. SteadyMed had a negative net margin of 3,179.76% and a negative return on equity of 226.48%. Analysts predict that SteadyMed will post ($1.56) EPS for the current year.
Several equities analysts recently issued reports on the company. ValuEngine lowered SteadyMed from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect SteadyMed (STDY) Share Price” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/10/31/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-steadymed-stdy-share-price.html.
SteadyMed Company Profile
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).
What are top analysts saying about SteadyMed Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SteadyMed Ltd. and related companies.